Myonexus Therapeutics, a clinical-stage gene therapy company developing first ever corrective gene therapies for limb girdle muscular dystrophies, and Nationwide Children’s Hospital announce the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Myonexus’ lead candidate, MYO-101, for the treatment of limb girdle muscular dystrophy (LGMD) type 2E.
To Read the Complete Article at EurekAlert!, Click Here
Working on a cure for a rare disease? Need Breakthrough Therapy designation, Fast Track Designation, RMAT Designation, FDA or EMA Orphan Designations? The BioPharma Global Regulatory Team can help – We are the #1 US based not-for-profit Global regulatory affairs firm with cost-effective, time-efficient solutions to chaperone your path through the regulatory affairs process. Contact us at https://biopharmaglobal.com/contact/ or by phone +1(202)660-1826
